This is a clinically supportive but non-catalytic data release. Watch for the full ASCO presentation on May 30 for potential incremental commercial sentiment. No pricing, revenue, or guidance change — near-term catalyst is the ASCO session.
Price Chart
Executive Summary
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59% overall response rate and 42.6-month median duration of response in r/r B-ALL patients with extramedullary disease. The abstract is a scientific presentation, not a regulatory event, but provides incremental clinical validation for a difficult-to-treat subpopulation.
Key Facts
- Post-hoc analysis of Phase Ib/II FELIX study (NCT04404660) evaluating obe-cel in r/r B-ALL patients with extramedullary disease (EMD).
- 27 of 127 infused patients (21%) had EMD at lymphodepletion.
- Overall response rate 59% and median duration of response 42.6 months in EMD patients.
- Abstract to be presented at ASCO Annual Meeting (May 29 – June 2, 2026) as Rapid Oral Abstract.
- Obe-cel is already a marketed therapy (AUCATZYL), so this is supportive data rather than a new approval event.
Financial Impact
No financial figures disclosed. The data supports obe-cel's clinical profile in EMD patients, which may modestly support commercial adoption but does not change near-term revenue guidance.
Risk Factors
- Post-hoc analysis carries lower evidence weight than prospective studies; no guarantee of label expansion.
- Competing CAR-T therapies (e.g., tisagenlecleucel, brexucabtagene autoleucel) already address B-ALL.
- Autolus has a $431M market cap and is pre-revenue at scale; commercial adoption of AUCATZYL is early-stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299801 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access